Dual-Function Fc-FGF21 Protein Production Without Protease Clipping

Resolve Bottlenecks,
Find Innovative Solutions
Generate Solutions

Solution Overview

Problem

Existing methods for producing recombinant proteins face challenges such as protease-mediated clipping, leading to heterogeneity and instability, which complicates production and purification, and conventional protease inhibitors are not effective due to cytotoxicity and removal difficulties.

Innovation Solution

A culture method using dextran sulfate in the medium for producing a recombinant dual function protein, comprising a fibroblast growth factor 21 (FGF21) mutant protein and an Fc region of an immunoglobulin, with specific mutations to enhance stability and reduce aggregation, is employed.

Engineering Contradictions & Design Principles

VSEngineering Contradiction Analysis

1Stability of the object's composition

If protease inhibitors are added to the culture medium to prevent protease-mediated clipping, then protein stability is improved, but cytotoxicity increases and product purification becomes more difficult

Engineering Contradiction:
Improveprotein stabilityVSAvoidcytotoxicity
Core Design Contradiction:
Stability of the object's compositionVSObject-affected harmful factors

Solution Approach 1:

The patent removes harmful protease inhibitors from the culture medium and instead extracts/eliminates the source of proteases by selecting host cells that do not secrete proteases during culture, thereby preventing protein clipping without introducing cytotoxic substances

Inventive Principle:
Principle #2Taking out (Extraction)

Solution Approach 2:

The patent introduces an intermediary solution by using specific host cell lines (CHO-DG44, CHO-K1, NSO, HEK293) that serve as a biological mediator to prevent protease-mediated clipping naturally, replacing the need for chemical protease inhibitors

Inventive Principle:
Principle #24Intermediary (Mediator)

2Stability of the object's composition

If protease inhibitors are used during production, then protein homogeneity is improved, but the complexity of the production process increases due to removal requirements

Engineering Contradiction:
Improveprotein homogeneityVSAvoidproduction process complexity
Core Design Contradiction:
Stability of the object's compositionVSDevice complexity

Solution Approach 1:

The patent eliminates the need for protease inhibitor removal steps from the production process by selecting host cells that do not secrete proteases, thereby maintaining protein homogeneity while simplifying the overall production workflow

Inventive Principle:
Principle #2Taking out (Extraction)

Solution Approach 2:

The host cell system is selected to naturally prevent protease-mediated clipping through its own biological properties (lack of protease secretion), making the system self-regulating and eliminating the need for external inhibitor management

Inventive Principle:
Principle #25Self-service

3Adaptability or versatility

If a universal method is applied to all target proteins, then adaptability is improved, but manufacturing precision may be compromised due to lack of optimization

Engineering Contradiction:
Improvemethod adaptabilityVSAvoidproduction precision
Core Design Contradiction:
Adaptability or versatilityVSManufacturing precision

Solution Approach 1:

The patent establishes a universal production method using mammalian host cells (CHO-DG44, CHO-K1, NSO, HEK293) that can produce various recombinant proteins with Fc regions or other heterologous regions without protease-mediated clipping, applicable across different target proteins while maintaining high production precision

Inventive Principle:
Principle #6Universality (Multi-functionality)

Data Source

PatentUS20260035429A1Method for producing dual function proteins and its derivatives
Publication Date: 2026.02.05 YUHAN CORPORATION
  • US20260035429A1 patent drawing
  • US20260035429A1 patent drawing
  • US20260035429A1 patent drawing

AI summary

A method for producing a dual function protein includes a biologically active protein and an FGF21 mutant protein. The method allows stable production of a target protein by effectively preventing decomposition of the target protein, and thus has a high potential for commercial usage.